Porcine Trypsin in the Manufacture of Biological Medicinal Products. Risks and Safety Requirements

Trypsin is a reagent widely used in the manufacture of biological medicinal products (BMPs). Until recently, pancreata of cattle, pigs and poultry were the main sources of trypsin preparations. The discovery of the disease called «transmissive spongiform encephalopathy» or «cow rabies» (TSE) in cattle in the late 1980s showed a clear need for limiting the use of this source. Given the potential risk of using trypsin obtained from cattle, porcine trypsin became more commonly used in the production of biological medicinal products. Enzymes obtained from raw materials of animal origin can be contaminated with circoviruses, parvo- and pestiviruses, and mycoplasmas that are common to pigs. Due to high resistance to physical and chemical treatment, these contaminants pose a potential risk to recipients of vaccines, as well as to other biological medicinal products. Prevention of contamination requires measures aimed at detection, reduction and inactivation of foreign agents, both in raw materials and during BMP production. The article considers the most common types of porcine trypsin contamination, methods of its detection, reduction and elimination. The article also contains information on the Russian and international requirements for the quality and safety of porcine trypsin used in the production of biological medicinal products.

1. Федеральный закон Российской Федерации от 12 апреля 2010 г. № 61-ФЗ «Об обращении лекарственных средств». [Federal law of the Russian Federation of April 12, 2010, No. 61-FZ «On circulation of medicines» (In Russ.)]

2. Recommendations for the Evaluation of Animal Cell Cultures as Substrates for the Manufacture of Biological Medicinal Products and for the Characterization of Cell Banks. WHO Technical Report. Series 978, Annex 3; 2013.

3. Суханова СМ, Петручук ЕМ, Генералов АА. Трипсин. Свойства и применение в производстве биологических лекарственных препаратов. БИОпрепараты. Профилактика, диагностика, лечение. 2018;18(2):106–13. [Sukhanova SM, Petruchuk EM, Generalov AA. Trypsin. Properties and Use in the Production of Biological Medicinal Products. BIOpreparations. Prevention, Diagnosis, Treatment. 2018;18(2):106–13 (In Russ.)]

4. Попова ВМ, Кочиш ИИ, Беро ИЛ, Самуйленко АЯ, Гуславский АИ. Разработка и оптимизация биотехнологий производства ветеринарных препаратов и ферментов. Сельскохозяйственная биология. 2010;(4):45–50. [Popova VM, Kochish II, Bero IL, Samuilenko AYa, Guslavskii AI. Development and optimization of biotechnology of manufacturing of veterinary preparation and enzymes. Sel’skokhozyaistvennaya biologiya = Agricultural Biology. 2010;(4):45–50 (In Russ.)]

5. Гребенникова ТВ. Современные аспекты диагностики прионных болезней. Симпозиум «Фундаментальные и прикладные исследования в области инфекционных болезней, эпидемиологии и микробиологии». Сочи; 2016. [Grebenniкova TV. Modern aspects of diagnosis of prion diseases. Symposium «Вasic and Applied Research in the Range of Infectious Diseases, Epidemiology and Microbiology». Sochi; 2016 (In Russ.)] Available from: http://iia-rf.ru/upload/iblock/ff8/ff85571904332a82859b870740670bc2.pdf

6. Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products (EMEA/410/01 rev. 3). EMA; 2011.

7. 5.2.8. Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and Veterinary Medicinal Products. European Pharmacopoeia 9.0.

8. Guideline on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products (EMA/CHMP/BWP/457920/2012). European Medicines Agency; 2013.

9. Guideline on the Use of Porcine Trypsin Used in the Manufacture of Human Biological Medicinal Products (EMA/CHMP/BWP/814397/2011). EMA; 2014.

10. Сатина ТА. Цирковирусные инфекции свиней: обзор литературы. Владимир: ФГУ ВНИИЗЖ; 2003. [Satina TA. Porcine Circovirus Diseases: Literature review. Vladimir: FGU VNIIZZH; 2003 (In Russ.)]

11. Victoria JG, Wang C, Jones MS, Jaing C, McLoughlin K, Gardner S, Delwart EL. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol. 2010;84(12):6033–40. https://doi.org/10.1128/JVI.02690-09

12. European Medicines Agency Confirms that Presence of Unexpected Viral DNA in Live Attenuated Vaccines Does not Raise Public Health Concerns. Press release (EMA/732522/2010). EMA; 2010.

13. Бутенков АИ. Патогенетическое обоснование развития и прогнозирования тяжести течения цирковирусной инфекции у поросят: дис. … д-ра вет. наук. Новочеркасск; 2010. [Butenkov AI. Pathogenetic substantiation of the development and prediction of the severity of the course of circovirus infection in piglets. Dr. Vet. Sci. [dissertation]. Novocherkassk; 2010 (In Russ.)]

14. Семенцов ВИ, Болоцкий ИА, Васильев АК, Пруцаков СВ. Цирковирусные болезни свиней (ЦВБС). Ветеринария Кубани. 2009;(5):8–10. [Sementsov VI, Bolotsky IA, Vasilyev AK, Prutsakov SV. Porcine circovirus diseases (PCVD). Veterinariya Kubani. 2009;(5):8–10 (In Russ.)]

15. Орлянкин БГ, Сергеев ВА, Седов ВА. Парвовирусная болезнь свиней. Ветеринария. 1987;10:72–6. [Orlyankin BG, Sergeev VA, Sedov VA. Porcine Parvovirus Infection. Veterinariya. 1987;10:72–6 (In Russ.)]

16. Brown TT Jr, Paul PS, Mengeling WL. Response of conventionally raised weanling pigs to experimental infection with a virulent strain of porcine parvovirus. Am J Vet Res. 1980;41(8):1221–4.

17. Ерофеев СГ. Парвовирусная инфекция свиней: эпизоотология, диагностика и специфическая профилактика: дис. …канд. вет. наук. Владимир; 2002. [Erofeev SG. Porcine parvovirus infection: epizootology, diagnosis and specific prophylaxis. Cand. Vet. Sci. [dissertation]. Vladimir; 2002 (In Russ.)]

18. Сидоров МА, Крупальник ВЛ. Чума свиней. В кн.: Бессарабов ВФ, Вашутин АА, Воронин ЕС. Инфекционные болезни животных. М.: КолосС; 2007. С. 362. [Sidorov MA, Krupalnik VL. Swine Fever. In: Bessarabov VF, Vashutin AA, Voronin ES. Infectious Diseases of Animals. Moscow: KolosS; 2007. P. 362 (In Russ.)]

19. Род пестивирусов. Медицинский справочник 4medical.in; 2012. [Pestiviruses. Medical Guide 4medical.in; 2012 (In Russ.)] Available from: http://4medical.in/rod-pestivirusov/

20. Жонголович АЕ. Этио-эпизоотологические особенности микоплазмоза свиней и усовершенствование методов его диагностики и лечения: дис. … канд. вет. наук. Омск; 2008. [Zhongolovich AE. Ethio-epizootological features of swine mycoplasmosis and improvement of methods of its diagnosis and treatment. Cand. Vet. Sci. [dissertation]. Omsk; 2008 (In Russ.)]

21. Ефанова ЛИ, Степанов АВ, Свиридов ММ, Манжурина ОА. Микоплазменная инфекция у свиней. Достижения науки и техники АПК. 2012;(1):35–6. [Efanova LI, Stepanov AV, Sviridov MM, Manzhurina OA. Mycoplasma infection in pigs. Dostizheniya nauki i tekhniki APK = Achievements of Science and Technology of AIC. 2012;(1):35–6 (In Russ.)]

22. Титов МА, Караулов АК, Шевцов АА, Бардина НС, Гуленкин ВМ, Дудников СА. Методические рекомендации по оценке безопасности на свиноводческих предприятиях в Российской Федерации. Владимир; 2010. [Titov MA, Karaulov AK, Shevtsov AA, Bardina NS, Gulenkin VM, Dudnikov SA. Methodological recommendations for the assessment of safety in pig farming enterprises in the Russian Federation. Vladimir; 2010 (In Russ.)]

23. Marcus-Sekura C, Richardson JC, Harston RK, Sane N, Sheets RL. Evaluation of the human host range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the manufacture of biological products. Biologicals. 2011;39(6):359–69. https://doi.org/10.1016/j.biologicals.2011.08.003

24. Правила надлежащей производственной практики Евразийского экономического союза (утв. Решением Совета Евразийской экономической комиссии от 3 ноября 2016 г. № 77). [Rules of Good Manufacturing Practice of the Eurasian Economic Union (app. by the Council of the Eurasian Economic Commission of November 3, 2016 No. 77) (In Russ.)]

25. Шалунова НВ, Меркулов ВА, Комратов АВ, Петручук ЕМ, Семенова ИС, Волгин АР, Трусов ГА. Требования к клеточным культурам, используемым для производства и контроля качества иммунобиологических лекарственных препаратов. Ведомости Научного центра экспертизы средств медицинского применения. 2013;(1):28–32. [Shalunova NV, Merkulov VA, Comratov AV, Petruchuk EM, Semenova IS, Volgin AR, Trousov GA. Requirements for cell cultures, used for manufacture and quality control of im munobiological medicines. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2013;(1):28–32 (In Russ.)]

26. Общая фармакопейная статья 1.7.2.0011.15 Требования к клеточным культурам — субстратам производства иммунобиологических лекарственных препаратов. Государственная фармакопея Российской Федерации. XIII изд. Т. 2, М.; 2015. [General monograph 1.7.2.0011.15 Requirements for cell cultures — substrates for the production of immunobiological drugs. The State Pharmacopoeia of Russian Federation 13th ed. V. 2. Moscow; 2015 (In Russ.)]

27. Петрова OГ, Донник ИМ, Исаева АГ, Крысенко ЮГ. Диагностика цирковирусной инфекции свиней. Аграрный вестник Урала. 2014;(3):27–31. [Petrova OG, Donnik IM, Isaeva AG, Krysenko YuG. Diagnostics of circovirus infection of pigs. Agrarnyj vestnik Urala = Agrarian Bulletin of the Urals. 2014;(3):27–31 (In Russ.)]

28. 01/2011:0694 Trypsin. European Pharmacopoeia 9.0.

29. 5.1.7. Viral safety. European Pharmacopoeia 9.0.

30. Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the In activation and Removal of Viruses (CPMP/BWP/268/95). EMA; 1996.

31. Гусаров ДА. Разработка научных основ создания технологии выделения и очистки генно-инженерных белков: дис. … д-ра хим. наук. М.; 2014. [Gusarov DA. Development of scientific bases of technology of isolation and purification of genetically engineered proteins. Dr. Chem. Sci. [dissertation]. Moscow; 2014 (In Russ.)]

32. Общая фармакопейная статья 1.2.4.0003.15 Стерильность. Государственная фармакопея Российской Федерации. XIII изд. Т. 1, М.; 2015. [General monograph 1.2.4.0003.15 Sterility. The State Pharmacopoeia of Russian Federation 13th ed. V. 1. Moscow; 2015 (In Russ.)]

33. Общая фармакопейная статья 1.7.2.0031.15 Испытание на присутствие микоплазм. Государственная фармакопея Российской Федерации. XIII изд. Т. 2, М.; 2015. [General monograph 1.7.2.0031.15 Test for the presence of my coplasma. The State Pharmacopoeia of Russian Federation 13th ed. V. 2. Moscow; 2015 (In Russ.)]

34. Производство протеолитических ферментных препаратов. [Manufacture of proteolytic enzyme preparations (InRuss.)] Available from: https://vuzlit.ru/716933/proizvodstvo_proteoliticheskih_fermentnyh_preparatov